MedTrace Logo

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

NCT07278479 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2026-05-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Conditions

  • Large Cell Neuroendocrine Carcinoma
  • Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
  • Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
  • Small Cell Lung Cancer (SCLC)
  • Gastroenteropancreatic NEC (GEP NEC)
  • NEC of the Bladder
  • Other DLL3 Expressing epNEC

Interventions

DRUG

[212Pb]Pb-MP0712

Radioligand Therapy

OTHER

[203Pb]Pb-MP0712

Radioligand Imaging Agent

Sponsors & Collaborators

  • Orano Med LLC

    collaborator INDUSTRY

  • Molecular Partners AG

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-18
Primary Completion
2028-09-30
Completion
2032-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07278479 on ClinicalTrials.gov